Cancer in the transplant recipient

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 7, 2013, Pages

  Chapman, Jeremy R ^a   Webster, Angela C ^a   Wong, Germaine ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; METHODOLOGY; NEOPLASM; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TRANSPLANTATION; VIRUS INFECTION;

EARLY DETECTION OF CANCER; HUMANS; IMMUNOSUPPRESSION; LIVING DONORS; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION; VIRUS DISEASES;

EID: 84879756272     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a015677     Document Type: Article

References (46)

1. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. 2003. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 89: 1221-1227.
2. Alberú J, PascoeMD, Campistol JM, Schena FP, RialMdel C, Polinsky M, Neylan JF, Korth-Bradley J, Godberg-Alberts R, Maller ES, et al. 2011. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-Month results from the CONVERT trial. Transplantation 92: 303-310.
3. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. 2009. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115: 2438-2446.
4. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S. 2008. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 8: 647-665.
5. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. 2012. Clinical practice guidelines on wait-listing for kidney transplantation: Consistent and equitable? Transplantation 94: 703-713.
6. Bunnapradist S, Danovitch GM. 2007. Evaluation of adult kidney transplant candidates. Am J Kidney Dis 50: 890-898.
7. Bunnapradist S, Vincenti F. 2009. Transplantation: To convert or not to convert: Lessons from the CONVERT trial. Nat Rev Nephrol 5: 371-373.
8. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. 2012. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 12: 1146-1156.
9. CARI Guidelines. 2011. Recipient assessment for transplantation. Available from http://www.cari.org.au/trans_recipient_suitability_underdev.php (last accessed February 15, 2012).
10. Collett D, Mumford L, Banner NR, Neuberger J, Watson C. 2010. Comparison of the incidence of malignancy in recipients of different types of organ: A UK registry audit. Am J Transplant 10: 1889-1896.
11. Collins MG, Teo E, Cole SR, Chan CY, McDonald SP, Russ GR, Young GP, Bampton PA, Coates PT. 2012. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: Cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy. BMJ 345: e4657.
12. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, et al. 2011. Spectrum of cancer risk among U.S. solid organ transplant recipients: The Transplant Cancer Match Study. JAMA 306: 1891-1901.
13. European Best Practice Guidelines (EBPG). 2000. Section I: Evaluation, selection and preparation of the potential renal transplant candidate. Nephrol Dial Transplant 15: 3-38.
14. PG Expert Group on Renal Transplantation. 2002. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: Prevention and treatment. Nephrol Dial Transplant 17: 32, 34-36.
15. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmarin A, et al. 2012. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367: 329-339.
16. Gallagher MP, Kelly PJ, Jardine M, Perkovic V, Cass A, Craig JC, Eris J, Webster AC. 2010. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 21: 852-858.
17. Guba M, Graeb C, Jauch KW, Geissler EK. 2004. Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77: 1777-1782.
18. Jiang Y, Villeneuve PJ, Wielgosz A, Schaubel DE, Fenton SSA, Mao Y. 2010. The incidence of cancer in a population-based cohort of Canadian heart transplant recipients. Am J Transplant 10: 637-645.
19. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG. 2000. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11: S1-S86.
20. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Vazquez MA, Weir MR, American Society of Transplantation. 2001. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant 1: 3-95.
21. Kauffman HM, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. 2002. Transplant tumor registry: Donor related malignancies. Transplantation 74: 358-362.
22. Kiberd BA, Rose C, Gill JS. 2009. Cancer mortality in kidney transplantation. Am J Transplant 9: 1868-1875.
23. Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, Rush D, Cole E, Kidney Transplant Working Group of the Canadian Society of Transplantation. 2005. Canadian Society of Transplantation: Consensus guidelines on eligibility for kidney transplantation. Can Med Assoc J 173: S1-S25.
24. Kyllönen L, Salmela K, Pukkala E. 2000. Cancer incidence in a kidney-transplanted population. Transpl Int 13: S394-S398.
25. Law BK. 2005. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 56: 47-60.
26. Miao Y, Everly JJ, Gross TG, TevarAD, First MR, Alloway RR, Woodle ES. 2009. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 87: 1347-1359.
27. MMOH. 2009. Renal replacement therapy-Clinical Practice Guidelines, 3rd ed. Malaysian Ministry of Health, Kuala Lumpur.
28. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. 2013. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. Am J Transplant 13: 174-183.
29. Nalesnik MA, Woodle ES, Dimaio JM, Vasudev B, Teperman LW, Covington S, Taranto S, Gockerman JP, Shapiro R, Sharma V, et al. 2011. Donor-transmitted malignancies in organ transplantation: Assessment of clinical risk. Am J Transplant 11: 1140-1147.
30. Opelz G, Döhler B. 2004. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4: 222-230.
31. Penn I. 1993. The effect of immunosuppression on pre-existing cancers. Transplantation 55: 742-747.
32. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. 2002. Non-melanoma skin cancer risk in theQueensland renal transplant population. Br J Dermatol 147: 950-956.
33. Rao RD, Buckner JC, Sarkaria JN. 2004. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4: 621-635.
34. Simeone E, Ascierto PA. 2012. Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 9: 241-247.
35. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th ed. International Agency for Research on Cancer, Lyon, France.
36. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. 2006. Cancer incidence before and after kidney transplantation. JAMA 296: 2823-2831.
37. van de Wetering J, Roodnat JI, Hemke AC, Hoitsma AJ, Weimar W. 2010. Patient survival after the diagnosis of cancer in renal transplant recipients: A nested case-control study. Transplantation 90: 1542-1546.
38. Van Leeuwen MT, Webster AC, McCredie MRE, Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM, Grulich AE. 2010. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: Population based retrospective cohort study. BMJ 340: c570.
39. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. 2007. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 7: 941-948.
40. Wang Y, Wang XY, Subjeck JR, Shrikant PA, Kim HL. 2011. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Cancer 104: 643-652.
41. Webster AC, Wong G. 2008. Cancer: ANZDATA registry 2008 report. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia.
42. Webster AC, Craig JC, Simpson JM, JonesMP, Chapman JR. 2007. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. AmJ Transplant 7: 2140-2151.
43. Wong G, Howard K, Craig JC, Chapman JR. 2008. Costeffectiveness of colorectal cancer screening in renal transplant recipients. Transplantation 85: 532-541.
44. Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, Craig JC. 2009a. Association of CKD and cancer risk in older people. J AmSoc Nephrol 20: 1341-1350.
45. Wong G, Howard K, Webster A, Chapman JR, Craig JC. 2009b. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation 87: 1078-1091.
46. Wong G, Howard K, Webster AC, Chapman JR, Craig JC. 2011. Screening for renal cancer in recipients of kidney transplants. Nephrol Dial Transplant 26: 1729-1739.